Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Sales and Divestitures: 2024

Historic Gains from Sales and Divestitures for Stoke Therapeutics (STOK) over the last 1 years, with Dec 2024 value amounting to $748,238.

  • Stoke Therapeutics' Gains from Sales and Divestitures was N/A to $748,238 in Q4 2024 from the same period last year, while for Dec 2024 it was $748,238, marking a year-over-year change of. This contributed to the annual value of $748,238 for FY2024, which is N/A change from last year.
  • Stoke Therapeutics' Gains from Sales and Divestitures amounted to $748,238 in FY2024.
  • In the past 5 years, Stoke Therapeutics' Gains from Sales and Divestitures registered a high of $748,238 during FY2024, and its lowest value of $748,238 during FY2024.
  • Its 1-year average for Gains from Sales and Divestitures is $748,238, with a median of $748,238 in 2024.